Valuation: PTC Therapeutics, Inc.

Market Cap 567.62Cr 493.43Cr 459.28Cr 421.67Cr 796.29Cr 54TCr 808.63Cr 5.41TCr 2.12TCr 27TCr 2.13TCr 2.08TCr 90TCr P/E 2026 *
41.2x
P/E 2027 * 24.6x
Enterprise Value 380.51Cr 330.77Cr 307.88Cr 282.67Cr 533.8Cr 36TCr 542.07Cr 3.63TCr 1.42TCr 18TCr 1.43TCr 1.4TCr 61TCr EV / Sales 2026 *
3.07x
EV / Sales 2027 * 2.61x
Free-Float
92.05%
Yield 2026 *
-
Yield 2027 * -
1 day-9.94%
1 week-11.47%
1 month-16.62%
3 months+4.53%
6 months-9.96%
Current year-10.47%
1 week 64.57
Extreme 64.5675
79.33
1 month 64.57
Extreme 64.5675
90.87
Current year 61.43
Extreme 61.43
90.87
1 year 43.18
Extreme 43.175
90.87
3 years 17.53
Extreme 17.53
90.87
5 years 17.53
Extreme 17.53
90.87
10 years 4.03
Extreme 4.03
90.87
Manager TitleAgeSince
Chief Executive Officer 54 22/03/2023
Director of Finance/CFO 41 13/07/2023
Chief Tech/Sci/R&D Officer - 01/10/2017
Director TitleAgeSince
Chairman 74 01/11/2004
Chairman 80 31/03/1998
Director/Board Member 65 01/12/2005
Date Insider Type Main position Quantity % Market Cap.
28/07/26 Other

Director

2,00,401 0.2416%
28/07/26 Free

Director

11,213 0.0135%
14/07/26 Sell

Chief Financial Officer

-3,494 0.0042%
Change 5-day change 1-year change 3-year change Capi.($)
-9.94%-11.47%+30.51%+68.59% 567.7Cr
-0.53%-3.95%+55.23%+152.74% 1,02400Cr
+0.21%-2.68%+55.61%+53.02% 62TCr
-2.51%-3.25%+32.76%+67.76% 44TCr
+0.06%-0.42%+37.53%+30.67% 35TCr
-0.14%-0.24%+34.41%+39.01% 30TCr
-0.69%-0.30%+11.55%+12.93% 26TCr
-7.37%-4.40%-2.54%-43.87% 21TCr
-0.64%+2.43%+30.52%+64.49% 21TCr
-0.82%+0.70%+15.96%+71.01% 16TCr
Average -2.24%-2.22%+30.15%+51.64% 35.79TCr
Weighted average by Cap. -1.00%-1.95%+39.22%+72.95%

Financials

2026 *2027 *
Net sales 124.05Cr 107.83Cr 100.37Cr 92Cr 174.02Cr 12TCr 176.72Cr 1.18TCr 464.34Cr 5.9TCr 465.87Cr 455.64Cr 20TCr 135.13Cr 117.47Cr 109.34Cr 100.38Cr 189.57Cr 13TCr 192.5Cr 1.29TCr 505.81Cr 6.42TCr 507.49Cr 496.34Cr 22TCr
Net income 13Cr 12Cr 11Cr 9.83Cr 19Cr 1.26TCr 19Cr 126.23Cr 50Cr 628.98Cr 50Cr 49Cr 2.11TCr 19Cr 17Cr 16Cr 14Cr 27Cr 1.86TCr 28Cr 185.45Cr 73Cr 924.07Cr 73Cr 71Cr 3.1TCr
Net Debt -187.11Cr -162.66Cr -151.4Cr -139Cr -262.49Cr -18TCr -266.56Cr -1.78TCr -700.39Cr -8.89TCr -702.71Cr -687.28Cr -30TCr -214.54Cr -186.5Cr -173.59Cr -159.38Cr -300.97Cr -20TCr -305.63Cr -2.05TCr -803.06Cr -10TCr -805.72Cr -788.02Cr -34TCr
Logo PTC Therapeutics, Inc.
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
Employees
991
Date Price Change Volume
31/26/31 $68.01 -9.94% 43,29,705
30/26/30 $75.52 +1.38% 13,74,880
29/26/29 $74.49 -1.19% 11,73,858
28/26/28 $75.39 -0.54% 14,87,692
27/26/27 $75.80 -1.33% 18,52,688
Trader
Investor
Global
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
68.01USD
Average target price
96.93USD
Spread / Average Target
+42.52%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PTCT Stock